Lung function decline in early HIV infection: Impact of antiretroviral drug timing and drug regimen

INSIGHT START Pulmonary Substudy Group

Research output: Contribution to journalArticlepeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)739-741
Number of pages3
JournalAmerican journal of respiratory and critical care medicine
Volume201
Issue number6
Early online dateDec 16 2019
DOIs
StatePublished - Mar 15 2020

Bibliographical note

Funding Information:
The START (Strategic Timing of Antiretroviral Treatment) Pulmonary Substudy was supported by the NHLBI (R01 HL096453); the parent START trial was primarily supported by the National Institute of Allergy and Infectious Diseases Division of AIDS (UM1 AI068641 and UM AI120197), with additional support from the German Ministry of Education and Research, the European AIDS Treatment Network (NEAT), the Australian National Health and Medical Research Council, and the UK Medical Research Council and National Institute for Health Research. The Veterans Health Administration Office of Research and Development also provided protected research time in support of this study. The University of Minnesota served as sponsor of the study. None of the funders nor the sponsor had any input regarding the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not reflect the views of the U.S. Government, the NIH, the Department of Veterans Affairs, the funders, the sponsors, or any of the authors’ affiliated academic institutions.

Funding Information:
Supported by a grant from the National Institute of Environmental Health Sciences, NIH (P30ES000002).

PubMed: MeSH publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Cite this